Search

Your search keyword '"Ciccarese F"' showing total 353 results
Start Over Author "Ciccarese F"
353 results on '"Ciccarese F"'

5. Correction to: Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Sleeve + Rossetti Fundoplication on Weight Loss and De Novo GERD in Patients Affected by Morbid Obesity: a Randomized Clinical Study (Obesity Surgery, (2022), 32, 5, (1451-1458), 10.1007/s11695-022-05955-8)

Author

Olmi S., Olmi, S, Cesana, G, Gambioli, A, Bonaldi, M, Ferrari, D, Uccelli, M, Ciccarese, F, De Carli, S, Giorgi, R, Mantovani, L, Olmi S., Cesana G., Gambioli A., Bonaldi M., Ferrari D., Uccelli M., Ciccarese F., De Carli S., Giorgi R., Mantovani L., Olmi S., Olmi, S, Cesana, G, Gambioli, A, Bonaldi, M, Ferrari, D, Uccelli, M, Ciccarese, F, De Carli, S, Giorgi, R, Mantovani, L, Olmi S., Cesana G., Gambioli A., Bonaldi M., Ferrari D., Uccelli M., Ciccarese F., De Carli S., Giorgi R., and Mantovani L.

Abstract

1) The correct names of the last three listed authors are: First name: Stefano, last name: De Carli First name: Riccardo, last name: Giorgi First name: Lorenzo, last name: Mantovani 2) Below is the correct table number 2. The corrections are: In the line “A esophagitis” and column “SG + RF (n 138),” the correct version is: 100%, 1/1. In the line “B esophagitis” and column “SG + RF (n 138),” the correct version is: 0%, 0/1.

Published
2022

6. COVID-19 and Obesity: Is Bariatric Surgery Protective? Retrospective Analysis on 2145 Patients Undergone Bariatric-Metabolic Surgery from High Volume Center in Italy (Lombardy)

Author

Uccelli, M, Cesana, G, De Carli, S, Ciccarese, F, Oldani, A, Zanoni, A, Giorgi, R, Villa, R, Ismail, A, Targa, S, D'Alessio, A, Mantovani, L, Olmi, S, Uccelli M., Cesana G. C., De Carli S. M., Ciccarese F., Oldani A., Zanoni A. A. G., Giorgi R., Villa R., Ismail A., Targa S., D'Alessio A., Cesana G., Mantovani L., Olmi S., Uccelli, M, Cesana, G, De Carli, S, Ciccarese, F, Oldani, A, Zanoni, A, Giorgi, R, Villa, R, Ismail, A, Targa, S, D'Alessio, A, Mantovani, L, Olmi, S, Uccelli M., Cesana G. C., De Carli S. M., Ciccarese F., Oldani A., Zanoni A. A. G., Giorgi R., Villa R., Ismail A., Targa S., D'Alessio A., Cesana G., Mantovani L., and Olmi S.

Abstract

Introduction: On February 20, 2020, a severe case of pneumonia due to SARS-CoV-2 was diagnosed in northern Italy (Lombardy). Some studies have identified obesity as a risk factor for severe disease in patients with COVID-19. The purpose of this study was to investigate the incidence of SARS-CoV-2 infection and its severity in patients who have undergone bariatric surgery. Material and Methods: During the lockdown period (until May 2020), we contacted operated patients by phone and social networks (e.g., Facebook) to maintain constant contact with them; in addition, we gave the patients a dedicated phone number at which to call us for emergencies. We produced telemedicine and educational videos for obese and bariatric patients, and we submitted a questionnaire to patients who had undergone bariatric surgery in the past. Results: A total of 2145 patients (313 male; 1832 female) replied to the questionnaire. Mean presurgical BMI: 44.5 ± 6.8 kg/m2. Mean age: 44.0 ± 10.0 year. Mean BMI after surgery: 29.3 ± 5.5 kg/m2 (p < 0.05). From February to May 2020, 8.4% of patients reported that they suffered from at least one symptom among those identified as related to SARS-CoV-2 infection. Thirteen patients (0.6%) tested positive for COVID-19. Six patients (0.3%) were admitted to the COVID Department, and 2 patients (0.1%) were admitted to the ICU. Conclusions: Although the reported rates of symptoms and fever were high, only 0.6% of patients tested positive for COVID-19. Among more than 2000 patients who underwent bariatric surgery analyzed in this study, only 0.1% needed ICU admission.

Published
2021

7. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

Author

Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C., Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, and Zamparelli, Marco Sanduzzi

Published
2017
Full Text
View/download PDF

8. Topic: Incisional Hernia — “Easy case” as daily case: open vs lap, where the mesh, which fixation…in center midline cases

Author

Yunis, J., Yamamoto, K., Morishima, Y., Satomi, D., Toshimitsu, Y., Fukutomi, S., Sakakibara, M., Mori, M., Ishige, K., Kobayashi, J., Uccelli, M., Ciccarese, F., Cesana, G., Castello, G., Carrieri, D., Grava, G., Olmi, S., Soliani, G., De Troia, A., Carcoforo, P., Portinari, M., Vasquez, G., Targa, S., Feo, C. V., Duarte de Castro L, B. Simões, Brito, T., Gomes, D., Calais, L., Ferreira, M., Gonçalves, A., Martins, A., Gonçalves, M., Rodrigues, A., Rodrigues, R., Almeida, T., Ventura, J., Lucas, C., Midões, A., Pileci, S., Giaccone, M., Brunetti, M., Camandona, M., Gasparri, G., Ucceli, M., Legnani, G., Nakabayashi, Y., Harada, A., Fujiwara, Y., Sugano, H., Matsumoto, N., Noaki, R., Kurihara, K., Otsuka, M., Mavrodin, C., Pariza, G., Antoniac, I., Dirican, A., Ates, M., Soyer, V., Sarici, B., Kinaci, E., Yilmaz, S., Matsumoto, M., Kazunao, K., Demiryas, S., Demir, I., Kucuk, Y., Umman, V., Orhan, A., Zengin, A. K., Ertem, M., Tasci, I., Christoffersen, M., Brandt, E., Oehlenschläger, J., Rosenberg, J., Helgstrand, F., Jørgensen, L. N., Bardram, L., Bisgaard, T., Bellanova, G., Valduga, R., Beltempo, R., Berlanda, G., Ciarleglio, F. A., Bondioli, R., Marcucci, S., Prezzi, C., and Brolese, A.

Published
2015
Full Text
View/download PDF

9. Inguinal Hernia: Mesh Fixation

Author

Sun, P., Hu, S. B., Cheng, X., Li, M., Guo, B., Song, Z. F., Zhang, Y., Zheng, Q. C., Hoyuela, C., Vega, L., Carvajal, F., Blay, L., Juvany, M., Camps, J., Veres, A., Besora, P., Trias, M., Feliu, X., Bellanova, G., Viel, G., Fabris, L., Valduga, P., Ciarleglio, F. A., Beltempo, P., Prezzi, C., Berlanda, G., Marcucci, S., Bondioli, P., Brolese, A., Agresta, F., Verza, L. A., Azabdaftari, A., Prando, D., Roveran, M. A., Rubinato, L., Vacca, U., Cesana, G., Ciccarese, F., Uccelli, M., Carrieri, D., Castello, G., Grava, G., Bonfanti, G., Legnani, G., Olmi, S., Chiaretti, M., Martinelli, A., Carru, G. A., Fegatelli, D. Alunni, Chiaretti, A. M., Consentino, P., Chiaretti, A. I., Procacciante, F., Blair, L., Huntington, C., Cox, T., Lincourt, A., Prasad, T., Matthews, B., Augenstein, V., Heniford, B. T., Verhagen, T., Loos, M. J. A., Scheltinga, M. R. M., Roumen, R. M. H., Magalhães, C., Pereira, S., Cardoso, G., Flores, A., Marcos, M., Lionetti, R., Cesaro, A., Napolitano, E., Caruso, L., Neola, B., Rutigliano, M., Ferulano, G. P., Pecic, V., Jovanovic, S., Filipovic, N., Trenkic, M., Pavlovic, A., Jovanovc, B., Tatic, M., Jovanovic, A., Khan, A., Tansawet, A., Lerdsirisopon, S., Techapongsatorn, S., Kasetsermwirija, W., Srimontayamas, S., Loapeamthong, C. U. S., Teawprasert, P., Bellomo, M. P., Bona, A., Borasi, A., Borreca, D., Filippa, C., Manfredi, S., De Paolis, P., Teng, A., Yu, J. W., Hu, Y., Sun, C. L., Zhou, J., Zha, X. G., Li, Y., Wu, J. Z., Abbonante, F., Kosai, N., Yussra, Y., Sutton, P. A., Shabbar, H. F., Razrim, R., Mustaffa, T., Tamil, A., Reynu, R., Abusalih, A., Shen, Y., Chen, J., Yang, S., Wang, M. G., Chen, F. Q., Fenger, A., Helvind, N. M., Pommergaard, H.-C., Burcharth, J., and Rosenberg, J.

Published
2015
Full Text
View/download PDF

10. Incisional Hernia: Difficult Cases 2

Author

Novitsky, Y., Fayezizadeh, M., Majumder, A., Yee, S., Petro, C., Orenstein, S., Woeste, G., Reinisch, A., Bechstein, W. O., Rosen, M., Carbonell, A., Cobb, W., Bauer, J., Selzer, D., Chao, J., Harmaty, M., Poulose, B., Matthews, B., Goldblatt, M., Jacobsen, G., Rosman, C., Hansson, B., Prabhu, A., Fathi, A., Skipworth, J., Younis, I., Floyd, D., Shankar, A., Olmi, S., Cesana, G., Ciccarese, F., Uccelli, M., Carrieri, D., Castello, G., Legnani, G., Lyo, V., Irwin, C., Xu, X., Harris, H., Zuvela, M., Galun, D., Petrovic, J., Palibrk, I., Koncar, I., Basaric, D., Tian, W., Fei, Y., Pittman, M., Jones, E., Schwartz, J., Mikami, D., Perrakis, A., Knüttel, D., Klein, P., Croner, R. S., Hohenberger, W., Perrakis, E., Müller, V., Grande, M., Villa, M., Lisi, G., Esser, A., De Sanctis, F., Petrella, G., Birolini, C., Miranda, J. S., Tanaka, E. Y., Utiyama, E. M., Rasslan, S., Shi, Y., Guo, X. B., Zhuo, H. Q., Li, L. P., Liu, H. J., Bauder, A., Gerety, P., Epps, G., Pannucci, C., Fischer, J., and Kovach, S.

Published
2015
Full Text
View/download PDF

11. Topic: Inguinal Hernia — Unsolved problem in the daily practice

Author

Yasuo, S., Kenichi, Y., Ueno, N., Arimoto, A., Hosono, M., Yoshikawa, T., Toyokawa, A., Kakeji, Y., Tsai, Y., Tsai, C., Sul, J., Lim, M., Park, J., Jang, C. E., Santilli, O., Tripoloni, D., Santilli, H., Nardelli, N., Greco, A., Estevez, M., Sakurai, S., Ryu, S., Cesana, G., Ciccarese, F., Uccelli, M., Grava, G., Castello, G., Carrieri, D., Legnani, G., Olmi, S., Naito, M., Yamamoto, H., Sawada, Y., Mandai, Y., Asano, H., Ino, H., Tsukuda, K., Nagahama, T., Ando, M., Ami, K., Arai, K., Miladinovic, M., Kitanovic, A., Lechner, M., Mayer, F., Meissnitzer, M., Fortsner, R., Öfner, D., Köhler, G., Jäger, T., Kumata, Y., Fukushima, R., Inaba, T., Yaguchi, Y., Horikawa, M., Ogawa, E., Katayama, T., Kumar, P. S., Unal, D., Caparlar, C., Akkaya, T., Mercan, U., Kulacoglu, H., Barreiro, J. Jorge, Baer, I. García, García, L. Solar, Cumplido, P. Lora, Florez, L. J. García, Muñiz, P. Fernandez, Fujino, K., Mita, K., Ohta, E., Takahashi, K., Hashimoto, M., Nagayasu, K., Murabayashi, R., Asakawa, H., Koizumi, K., Hayashi, G., Ito, H., Felberbauer, F., Strobl, S., Kristo, I., Riss, S., Prager, G., El Komy, H., El Gendi, A., Nabil, W., Karam, M., El Kayal, S., Chihara, N., Suzuki, H., Watanabe, M., Uchida, E., Chen, T., Wang, J., Wang, H., Bouchiba, N., Elbakary, T., Ramadan, A., Elakkad, M., Berney, C., Vlasov, V., Babii, I., Pidmurnyak, O., Prystupa, M., Asakage, N., Molinari, P., Contino, E., Guzzetti, L., Oggioni, M., Sambuco, M., Berselli, M., Farassino, L., Cocozza, E., Crespi, A., Ambrosoli, A., and Zhao, Y.

Published
2015
Full Text
View/download PDF

12. Sustained oxygenation improvement after first prone positioning is associated with liberation from mechanical ventilation and mortality in critically ill COVID-19 patients: a cohort study

Author

Scaramuzzo G., Gamberini L., Tonetti T., Zani G., Ottaviani I., Mazzoli C. A., Capozzi C., Giampalma E., Bacchi Reggiani M. L., Bertellini E., Castelli A., Cavalli I., Colombo D., Crimaldi F., Damiani F., Fusari M., Gamberini E., Gordini G., Laici C., Lanza M. C., Leo M., Marudi A., Nardi G., Papa R., Potalivo A., Russo E., Taddei S., Consales G., Cappellini I., Ranieri V. M., Volta C. A., Guerin C., Spadaro S., Tartaglione M., Chiarini V., Buldini V., Coniglio C., Moro F., Barbalace C., Citino M., Cilloni N., Giuntoli L., Bellocchio A., Matteo E., Pizzilli G., Siniscalchi A., Tartivita C., Matteo F., Marchio A., Bacchilega I., Bernabe L., Guarino S., Mosconi E., Bissoni L., Viola L., Meconi T., Pavoni V., Pagni A., Pompa Cleta P., Cavagnino M., Malfatto A., Adduci A., Pareschi S., Melegari G., Maccieri J., Marinangeli E., Racca F., Verri M., Falo G., Marangoni E., Boni F., Felloni G., Baccarini F. D., Terzitta M., Maitan S., Becherucci F., Parise M., Masoni F., Imbriani M., Orlandi P., Monetti F., Dalpiaz G., Golfieri R., Ciccarese F., Poerio A., Muratore F., Ferrari F., Mughetti M., Franchini L., Neziri E., Miceli M., Minguzzi M. T., Mellini L., Piciucchi S., Bartolucci M., Scaramuzzo G., Gamberini L., Tonetti T., Zani G., Ottaviani I., Mazzoli C.A., Capozzi C., Giampalma E., Bacchi Reggiani M.L., Bertellini E., Castelli A., Cavalli I., Colombo D., Crimaldi F., Damiani F., Fusari M., Gamberini E., Gordini G., Laici C., Lanza M.C., Leo M., Marudi A., Nardi G., Papa R., Potalivo A., Russo E., Taddei S., Consales G., Cappellini I., Ranieri V.M., Volta C.A., Guerin C., Spadaro S., Tartaglione M., Chiarini V., Buldini V., Coniglio C., Moro F., Barbalace C., Citino M., Cilloni N., Giuntoli L., Bellocchio A., Matteo E., Pizzilli G., Siniscalchi A., Tartivita C., Matteo F., Marchio A., Bacchilega I., Bernabe L., Guarino S., Mosconi E., Bissoni L., Viola L., Meconi T., Pavoni V., Pagni A., Pompa Cleta P., Cavagnino M., Malfatto A., Adduci A., Pareschi S., Melegari G., Maccieri J., Marinangeli E., Racca F., Verri M., Falo G., Marangoni E., Boni F., Felloni G., Baccarini F.D., Terzitta M., Maitan S., Becherucci F., Parise M., Masoni F., Imbriani M., Orlandi P., Monetti F., Dalpiaz G., Golfieri R., Ciccarese F., Poerio A., Muratore F., Ferrari F., Mughetti M., Franchini L., Neziri E., Miceli M., Minguzzi M.T., Mellini L., Piciucchi S., and Bartolucci M.

Subjects
medicine.medical_specialty, Supine position, COVID19, medicine.medical_treatment, Respiratory physiology, Prone positioning, ventilatory free days, Critical Care and Intensive Care Medicine, ICU, COVID19, Prone positioning, ventilatory free days, NO, 03 medical and health sciences, 0302 clinical medicine, Anesthesiology, medicine, 030212 general & internal medicine, Mechanical ventilation, business.industry, RC86-88.9, Research, Medical emergencies. Critical care. Intensive care. First aid, Oxygenation, respiratory system, respiratory tract diseases, Prone position, 030228 respiratory system, Anesthesia, ICU, Complication, business, Cohort study
Abstract

Background Prone positioning (PP) has been used to improve oxygenation in patients affected by the SARS-CoV-2 disease (COVID-19). Several mechanisms, including lung recruitment and better lung ventilation/perfusion matching, make a relevant rational for using PP. However, not all patients maintain the oxygenation improvement after returning to supine position. Nevertheless, no evidence exists that a sustained oxygenation response after PP is associated to outcome in mechanically ventilated COVID-19 patients. We analyzed data from 191 patients affected by COVID-19-related acute respiratory distress syndrome undergoing PP for clinical reasons. Clinical history, severity scores and respiratory mechanics were analyzed. Patients were classified as responders (≥ median PaO2/FiO2 variation) or non-responders (2/FiO2 variation) based on the PaO2/FiO2 percentage change between pre-proning and 1 to 3 h after re-supination in the first prone positioning session. Differences among the groups in physiological variables, complication rates and outcome were evaluated. A competing risk regression analysis was conducted to evaluate if PaO2/FiO2 response after the first pronation cycle was associated to liberation from mechanical ventilation. Results The median PaO2/FiO2 variation after the first PP cycle was 49 [19–100%] and no differences were found in demographics, comorbidities, ventilatory treatment and PaO2/FiO2 before PP between responders (96/191) and non-responders (95/191). Despite no differences in ICU length of stay, non-responders had a higher rate of tracheostomy (70.5% vs 47.9, P = 0.008) and mortality (53.7% vs 33.3%, P = 0.006), as compared to responders. Moreover, oxygenation response after the first PP was independently associated to liberation from mechanical ventilation at 28 days and was increasingly higher being higher the oxygenation response to PP. Conclusions Sustained oxygenation improvement after first PP session is independently associated to improved survival and reduced duration of mechanical ventilation in critically ill COVID-19 patients.

Published
2021

13. Follow-up of bone mineral density and body composition in adolescents with restrictive anorexia nervosa: role of dual-energy X-ray absorptiometry

Author

Franzoni, E., Ciccarese, F., Di Pietro, E., Facchini, G., Moscano, F., Iero, L., Monaldi, A., Battista, G., and Bazzocchi, A.

Subjects
Anorexia nervosa -- Physiological aspects -- Diagnosis, Bones -- Density, Bone densitometry -- Methods, Food/cooking/nutrition, Health
Abstract

BACKGROUND/OBJECTIVES: Restrictive Anorexia nervosa (ANR) is an eating disorder (ED) characterized by a low bone mineral content (BMC) and by an alteration in body composition (reduction and abnormal distribution of fat mass--FM and lean mass--LM). The aim of our study was to address whether bone and body composition changes could be influenced by hormonal status and sport in female adolescents with restrictive anorexia nervosa-ANR. SUBJECTS/METHODS: Prospective study on 79 adolescents with ANR submitted to Dual Energy X-Ray Absorptiometry--DXA at baseline-T0 and after 12 months-T12. Among the 46/79-58.2% patients that completed the study, we evaluated total and regional FM and LM%, as well as lumbar bone mineral density (BMD) and Z-score, linking them to clinical variables: menarche/amenorrhea/ hormonal therapy and physical activity. RESULTS: At T0: body mass index (BMI) = 16.4 ± 1.4 kg/[m.sup.2] with low levels of FM% (21.7 ± 5.7) low BMC in 12/46-26.0% (mean Z-score: - 1.21 ±1.27, with higher values related to physical activity--P = 0.001). At T12: a significant increase in BMI--P = 0.001, with LM reduction and FM increase (more evident in the trunk--P CONCLUSIONS: After 1 year, weight recovery was not associated with a reestablishment of bone values; by contrast, it was associated with an increase and a distortion in FM distribution, more evident in trunk region (potential and adjunctive risk factor for the relapse of the psychiatric condition). The complexity of these clinical findings suggested DXA, a low-dose and low-cost technique, in long-term monitoring of ANR patients. European Journal of Clinical Nutrition (2014) 68, 247-252; doi: 10.1038/ejcn.2013.254; published online 18 December 2013 Keywords: dual-energy X-Ray absorptiometry; anorexia nervosa; pathologic bone demineralization; body composition, INTRODUCTION Restrictive Anorexia Nervosa (ANR) is a clinical mental disorder defined as abnormal eating behaviors that can be diagnosed only by strict criteria. (1) Eating disorders (ED) are behavioral syndromes [...]

Published
2014
Full Text
View/download PDF

14. Years of life that could be saved from prevention of hepatocellular carcinoma

Author

Cucchetti, A., Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

15. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

Author

Bucci, L., Garuti, F., Camelli, V., Lenzi, B., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Trevisani, F., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Roselli, Paola, Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pelagatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

17. Laparoscopic transperitoneal hernia repair (TAPP) in emergency: long-term follow-up in a high volume centre

Author

Zanoni, A. A. G., primary, Delcarro, A., additional, Ciccarese, F., additional, Villa, R., additional, Oldani, A., additional, Giorgi, R., additional, Rubicondo, C., additional, Bonaldi, M., additional, Cesana, G., additional, Uccelli, M., additional, De Carli, S., additional, Ismail, A., additional, Ferrari, D., additional, and Olmi, S., additional

Published
2021
Full Text
View/download PDF

22. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

Author

Giannini E. G., Bucci L., Garuti F., Brunacci M., Lenzi B., Valente M., Caturelli E., Cabibbo G., Piscaglia F., Virdone R., Felder M., Ciccarese F., Foschi F. G., Sacco R., Svegliati Baroni G., Farinati F., Rapaccini G. L., Olivani A., Gasbarrini A., Di Marco M., Morisco F., Zoli M., Masotto A., Borzio F., Benvegnu L., Marra F., Colecchia A., Nardone G., Bernardi M., Trevisani F, Olmi S, on behalf of Italian Liver Cancer (ITA. LI. CA) group, Giannini, E. G., Bucci, L., Garuti, F., Brunacci, M., Lenzi, B., Valente, M., Caturelli, E., Cabibbo, G., Piscaglia, F., Virdone, R., Felder, M., Ciccarese, F., Foschi, F. G., Sacco, R., Svegliati Baroni, G., Farinati, F., Rapaccini, G. L., Olivani, A., Gasbarrini, A., Di Marco, M., Morisco, F., Zoli, M., Masotto, A., Borzio, F., Benvegnu, L., Marra, F., Colecchia, A., Nardone, G., Bernardi, M., Trevisani, F, Olmi, S, on behalf of Italian Liver Cancer (ITA. LI., CA) group, Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F, Giannini, Edoardo G, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Baroni, Gianluca Svegliati, Farinati, Fabio, Rapaccini, Gian Lodovico, Olivani, Andrea, Gasbarrini, Antonio, Di Marco, Maria, Morisco, Filomena, Zoli, Marco, Masotto, Alberto, Borzio, Franco, Benvegnù, Luisa, Marra, Fabio, Colecchia, Antonio, Nardone, Gerardo, Bernardi, Mauro, and Trevisani, Franco

Subjects
Sorafenib, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Databases, Factual, Settore MED/12 - GASTROENTEROLOGIA, advanced stage, Gastroenterology, survival, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, Humans, Stage (cooking), Precision Medicine, Cancer staging, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, therapy, Hepatology, Performance status, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Liver cancer, sorafenib, Liver cancer, advanced stage, sorafenib, survival, therapy, Treatment Outcome, Liver, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Female, alpha-Fetoproteins, business, medicine.drug
Abstract

The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS], macro-vascular invasion [MVI], extra-hepatic spread [EHS] or MVI+EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analysed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were sub-classified as: PS1 alone (n=385, 46.1%), PS2 alone (n=146, 17.5%), MVI (n=224, 26.8%), EHS (n=51, 6.1%) and MVI+EHS (n=29, 3.5%). MVI, EHS and MVI+EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months) and MVI+EHS (3.1 months) (P

Published
2018

23. Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: multicenter observational study in fifteen Italian ICUs

Author

Gamberini, L., Tonetti, T., Spadaro, S., Zani, G., Mazzoli, C. A., Capozzi, C., Giampalma, E., Bacchi Reggiani, M. L., Bertellini, E., Castelli, A., Cavalli, I., Colombo, D., Crimaldi, F., Damiani, F., Fogagnolo, A., Fusari, M., Gamberini, E., Gordini, G., Laici, C., Lanza, M. C., Leo, M., Marudi, A., Nardi, G., Ottaviani, I., Papa, R., Potalivo, A., Russo, E., Taddei, S., Volta, C. A., Ranieri, V. M., Tartaglione, M., Chiarini, V., Buldini, V., Coniglio, C., Moro, F., Cilloni, N., Giuntoli, L., Bellocchio, A., Matteo, E., Pizzilli, G., Siniscalchi, A., Tartivita, C., Matteo, F., Marchio, A., Bacchilega, I., Bernabe, L., Guarino, S., Mosconi, G., Bissoni, L., Viola, L., Meconi, T., Pavoni, V., Pagni, A., Pompacleta, P., Cavagnino, M., Malfatto, A., Adduci, A., Pareschi, S., Melegari, G., Maccieri, J., Marinangeli, E., Racca, F., Verri, M., Falo, G., Marangoni, E., Boni, F., Felloni, G., Baccarini, F. D., Terzitta, M., Maitan, S., Imbriani, M., Orlandi, P., Dalpiaz, G., Golfieri, R., Ciccarese, F., Poerio, A., Muratore, F., Ferrari, F., Mughetti, M., Franchini, L., Neziri, E., Miceli, M., Minguzzi, M. T., Mellini, L., Piciucchi, S., Gamberini, Lorenzo, Tonetti, Tommaso, Spadaro, Savino, Zani, Gianluca, Mazzoli, Carlo Alberto, Capozzi, Chiara, Giampalma, Emanuela, Bacchi Reggiani, Maria Letizia, Bertellini, Elisabetta, Castelli, Andrea, Cavalli, Irene, Colombo, Davide, Crimaldi, Federico, Damiani, Federica, Fogagnolo, Alberto, Fusari, Maurizio, Gamberini, Emiliano, Gordini, Giovanni, Laici, Cristiana, Lanza, Maria Concetta, Leo, Mirco, Marudi, Andrea, Nardi, Giuseppe, Ottaviani, Irene, Papa, Raffaella, Potalivo, Antonella, Russo, Emanuele, Taddei, Stefania, Volta, Carlo Alberto, and Ranieri, V Marco

Subjects
medicine.medical_specialty, ARDS, medicine.medical_treatment, artificial, Outcomes, Critical Care and Intensive Care Medicine, law.invention, NO, 03 medical and health sciences, 0302 clinical medicine, Mechanical ventilation, law, Coronavirus disease 2019, Intensive care, Outcomes, mortality, Respiration, artificial, medicine, 030212 general & internal medicine, Renal replacement therapy, business.industry, Research, Respiration, Organ dysfunction, lcsh:Medical emergencies. Critical care. Intensive care. First aid, 030208 emergency & critical care medicine, lcsh:RC86-88.9, medicine.disease, Intensive care unit, mortality, Respiratory failure, Emergency medicine, SOFA score, medicine.symptom, business
Abstract

Background A large proportion of patients with coronavirus disease 2019 (COVID-19) develop severe respiratory failure requiring admission to the intensive care unit (ICU) and about 80% of them need mechanical ventilation (MV). These patients show great complexity due to multiple organ involvement and a dynamic evolution over time; moreover, few information is available about the risk factors that may contribute to increase the time course of mechanical ventilation. The primary objective of this study is to investigate the risk factors associated with the inability to liberate COVID-19 patients from mechanical ventilation. Due to the complex evolution of the disease, we analyzed both pulmonary variables and occurrence of non-pulmonary complications during mechanical ventilation. The secondary objective of this study was the evaluation of risk factors for ICU mortality. Methods This multicenter prospective observational study enrolled 391 patients from fifteen COVID-19 dedicated Italian ICUs which underwent invasive mechanical ventilation for COVID-19 pneumonia. Clinical and laboratory data, ventilator parameters, occurrence of organ dysfunction, and outcome were recorded. The primary outcome measure was 28 days ventilator-free days and the liberation from MV at 28 days was studied by performing a competing risks regression model on data, according to the method of Fine and Gray; the event death was considered as a competing risk. Results Liberation from mechanical ventilation was achieved in 53.2% of the patients (208/391). Competing risks analysis, considering death as a competing event, demonstrated a decreased sub-hazard ratio for liberation from mechanical ventilation (MV) with increasing age and SOFA score at ICU admission, low values of PaO2/FiO2 ratio during the first 5 days of MV, respiratory system compliance (CRS) lower than 40 mL/cmH2O during the first 5 days of MV, need for renal replacement therapy (RRT), late-onset ventilator-associated pneumonia (VAP), and cardiovascular complications. ICU mortality during the observation period was 36.1% (141/391). Similar results were obtained by the multivariate logistic regression analysis using mortality as a dependent variable. Conclusions Age, SOFA score at ICU admission, CRS, PaO2/FiO2, renal and cardiovascular complications, and late-onset VAP were all independent risk factors for prolonged mechanical ventilation in patients with COVID-19. Trial registration NCT04411459

Published
2020

24. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Author

Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F, Bolondi L, Biselli M, Bucci L, Caraceni P, Cucchetti A, Domenicali M, Venerandi L, Giacomin A, Maddalo G, Pozzan C, Vani V, Poggio PD, Olmi S, Balsamo C, Vavassori E, Benvegnù L, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Bosco G, Roselli P, Dell'Isola S, Ialungo AM, Bruzzone L, Picciotto A, Marenco S, Risso D, Sammito G, Savarino V, Cammà C, Maida M, Costantino A, Barcellona MR, Affronti A, Mega A, Rinninella E, Mismas V, Cappa FM, Dall'Aglio AC, Feletti V, Lanzi A, Neri E, Stefanini GF, Tamberi S, Missale G, Porro E, Guarino M, Gemini S, Schiadà L, for the Italian LiverCancer (ITA. LI. CA) group, Donatella Magalotti, Carla Serra, Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F, Bolondi L, Biselli M, Bucci L, Caraceni P, Cucchetti A, Domenicali M, Magalotti D, Serra C, Venerandi L, Giacomin A, Maddalo G, Pozzan C, Vani V, Poggio PD, Olmi S, Balsamo C, Vavassori E, Benvegnù L, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Bosco G, Roselli P, Dell'Isola S, Ialungo AM, Bruzzone L, Picciotto A, Marenco S, Risso D, Sammito G, Savarino V, Cammà C, Maida M, Costantino A, Barcellona MR, Affronti A, Mega A, Rinninella E, Mismas V, Cappa FM, Dall'Aglio AC, Feletti V, Lanzi A, Neri E, Stefanini GF, Tamberi S, Missale G, Porro E, Guarino M, Gemini S, Schiadà L, Pecorelli, A., Lenzi, B., Gramenzi, A., Garuti, F., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Morisco, F., Gasbarrini, A., Baroni, G. S., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Bernardi, M., Trevisani, F., Bolondi, L., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Magalotti, D., Serra, C., Venerandi, L., Giacomin, A., Maddalo, G., Pozzan, C., Vani, V., Poggio, P. D., Olmi, S., Balsamo, C., Vavassori, E., Benvegnu, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Bosco, G., Roselli, P., Dell'Isola, S., Ialungo, A. M., Bruzzone, L., Picciotto, A., Marenco, S., Risso, D., Sammito, G., Savarino, V., Camma, C., Maida, M., Costantino, A., Barcellona, M. R., Affronti, A., Mega, A., Rinninella, E., Mismas, V., Cappa, F. M., Dall'Aglio, A. C., Feletti, V., Lanzi, A., Neri, E., Stefanini, G. F., Tamberi, S., Missale, G., Porro, E., Guarino, M., Gemini, S., Schiada, L., Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G, Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, and Trevisani, Franco

Subjects
Sorafenib, Male, Niacinamide, medicine.medical_specialty, Standard of care, Carcinoma, Hepatocellular, Antineoplastic Agents, Gastroenterology, Intermediate stage, 03 medical and health sciences, 0302 clinical medicine, HCC, BCLC-B, Treatment, Hepatology, Internal medicine, medicine, Humans, Chemoembolization, Therapeutic, Propensity Score, Aged, Neoplasm Staging, Retrospective Studies, intermediate stage, treatment, business.industry, Patient Selection, Phenylurea Compounds, Liver Neoplasms, Settore MED/09 - MEDICINA INTERNA, Standard of Care, Middle Aged, medicine.disease, Survival Analysis, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Propensity score matching, Multivariate Analysis, 030211 gastroenterology & hepatology, Female, Liver function, Liver cancer, business, medicine.drug
Abstract

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follow-up before receiving treatment. Treatment distribution was: TACE (233, 51.1%), curative treatments (145 patients, 31.8%), sorafenib (18, 3.9%), other (39, 8.5%), best supportive care (BSC) (21, 4.6%). Median survival (95% CI) was 45 months (37.4-52.7) for curative treatments, 30 (24.7-35.3) for TACE, 14 (10.5-17.5) for sorafenib, 14 (5.2-22.7) for other treatments and 10 (6.0-14.2) for BSC (p

Published
2017

27. Topic: Incisional Hernia — Parastomal

Author

Evans, L., Swafe, L., Fielding, A., Speakman, C., Curado-Soriano, A., Infantes-Ormad, M., Valera-Sanchez, Z., Naranjo-Fernandez, J. R., Dominguez-Amodeo, A., Ruiz-Zafra, A., Navarrete-Carcer, E., Oliva-Mompean, F., Padillo-Ruiz, J., Ciccarese, F., Cesana, G., Uccelli, M., Carrieri, D., Castello, G., Bonfanti, G., Grava, G., Legnani, G., and Olmi, S.

Published
2015
Full Text
View/download PDF

28. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

Author

Morisco, Filomena, Camera, Silvia, Guarino, Maria, Tortora, Raffaella, Cossiga, Valentina, Vitiello, Anna, Cordone, Gabriella, Caporaso, Nicola, Di Costanzo, Giovan Giuseppe, Zoli, M., Garuti, F., Neri, A., Piscaglia, F., Lenzi, B., Valente, M., Trevisani, F., Bolondi, L., Biselli, M., Caraceni, P., Cucchetti, A., Domenicali, M., Gramenzi, A., Magalotti, D., Serra, C., Venerandi, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Giannini, E. G., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Caturelli, E., Roselli, P., Lauria, V., Pelecca, G., Dell'Isola, S., Ialungo, A. M., Rastrelli, E., Cabibbo, G., Cammà, C., Attardo, S., Rossi, M., Cavani, G., Virdone, R., Affronti, A., Nardone, G., Felder, M., Mega, A., Ciccarese, F., Del Poggio, P., Olmi, S., Foschi, F. G., Bevilacqua, V., Dall'Aglio, A. C., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Sacco, R., Mismas, V., Svegliati Barone, G., Schiadà, L., Farinati, F., Gazzola, A., Murer, F., Pozzan, C., Vanin, V., Rapaccini, G. L., de Matthaeis, N., Gasbarrini, A., Rinninella, E., Olivani, A., Missale, G., Biasini, E., Di Marco, M., Balsamo, C., Vavassori, E., Masotto, A., Marchetti, F., Valerio, M., Marra, F., Aburas, S., Campani, C., Dragoni, G., Borzio, F., Benvegnù, L., Festi, D., Marasco, Giovanni, Ravaioli, Federico, Morisco, Filomena, Camera, Silvia, Guarino, Maria, Tortora, Raffaella, Cossiga, Valentina, Vitiello, Anna, Cordone, Gabriella, Caporaso, Nicola, Di Costanzo, Giovan Giuseppe, Zoli, M., Garuti, F., Neri, A., Piscaglia, F., Lenzi, B., Valente, M., Trevisani, F., Bolondi, L., Biselli, M., Caraceni, P., Cucchetti, A., Domenicali, M., Gramenzi, A., Magalotti, D., Serra, C., Venerandi, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Giannini, E.G., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Caturelli, E., Roselli, P., Lauria, V., Pelecca, G., Dell'Isola, S., Ialungo, A.M., Rastrelli, E., Cabibbo, G., Cammà, C., Attardo, S., Rossi, M., Cavani, G., Virdone, R., Affronti, A., Nardone, G., Felder, M., Mega, A., Ciccarese, F., Del Poggio, P., Olmi, S., Foschi, F.G., Bevilacqua, V., Dall'Aglio, A.C., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Sacco, R., Mismas, V., Svegliati Barone, G., Schiadà, L., Farinati, F., Gazzola, A., Murer, F., Pozzan, C., Vanin, V., Rapaccini, G.L., de Matthaeis, N., Gasbarrini, A., Rinninella, E., Olivani, A., Missale, G., Biasini, E., Di Marco, M., Balsamo, C., Vavassori, E., Masotto, A., Marchetti, F., Valerio, M., Marra, F., Aburas, S., Campani, C., Dragoni, G., Borzio, F., Benvegnù, L., Festi, D., Marasco, Giovanni, Ravaioli, Federico, Giannini, E. G., Ialungo, A. M., Foschi, F. G., Dall'Aglio, A. C., Rapaccini, G. L., Garuti, Franca, Venerandi, Laura, Mega, Angela, Fiorini, Elisabetta, Lanzi, Andrea, and Balsamo, Carlo

Subjects
medicine.medical_specialty, Large HCC, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Survival rate, Laser ablation, TACE, Univariate analysis, business.industry, Standard treatment, Large HCC, Laser ablation, TACE, Oncology, Cancer, Hepatology, medicine.disease, BCLC Stage, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Liver cancer, business, Research Paper
Abstract

// Filomena Morisco 1 , Silvia Camera 1 , Maria Guarino 1 , Raffaella Tortora 2 , Valentina Cossiga 1 , Anna Vitiello 1 , Gabriella Cordone 2 , Nicola Caporaso 1 , Giovan Giuseppe Di Costanzo 2 and Italian Liver Cancer (ITA.LI.CA) group 1 Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy 2 Hepatology Unit, “Cardarelli” Hospital, Naples, Italy Correspondence to: Filomena Morisco, email: filomena.morisco@unina.it Keywords: large HCC; laser ablation; TACE Received: December 13, 2017 Accepted: February 27, 2018 Published: April 03, 2018 ABSTRACT Background: Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively ( p 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively ( p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC.

Published
2018

31. Metabolic disorders across hepatocellular carcinoma in Italy

Author

Morisco, F., Guarino, M., Valvano, M. R., Auriemma, F., Farinati, F., Giannini, E. G., Ciccarese, F., Tovoli, F., Rapaccini, Gian Ludovico, Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Benvengu, L., Gasbarrini, Antonio, Svegliati Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Marra, F., Caporaso, N., Trevisani, F., Sessa, A., Marafatto, F., Peserico, G., Pozzan, C., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Del Poggio, P., Olmi, S., De Matthaeis, Nicoletta, Balsamo, C., Vavassori, E., Roselli, P., Lauria, V., Pelecca, G., Mismas, V., Rossi, M., Attardo, S., Cavani, G., Mega, A., Rinninella, Emanuele, Ortolani, A., Bevilacqua, V., Chiara Dall'Aglio, A., Ercolani, G., Fiorini, Carlo Ettore, Casadei Gardini, A., Lanzi, Alessio, Mirici Cappa, F., Missale, G., Porro, E., Marchetti, F., Valerio, M., Affronti, A., Orlando, E., Rosa Barcellona, M., Aburas, S., Dragoni, G., Campani, C., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Garuti, F., Gramenzi, A., Magalotti, D., Serra, C., Granito, A., Negrini, G., Napoli, L., Piscaglia, F., Morisco, F., Guarino, M., Valvano, M. R., Auriemma, F., Farinati, F., Giannini, E. G., Ciccarese, F., Tovoli, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Benvengu, L., Gasbarrini, A., Svegliati Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Marra, F., Caporaso, N., Trevisani, F., Sessa, A., Marafatto, F., Peserico, G., Pozzan, C., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Del Poggio, P., Olmi, S., de Matthaeis, N., Balsamo, C., Vavassori, E., Roselli, P., Lauria, V., Pelecca, G., Mismas, V., Rossi, M., Attardo, S., Cavani, G., Mega, A., Rinninella, E., Ortolani, A., Bevilacqua, V., Chiara Dall'Aglio, A., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Missale, G., Porro, E., Marchetti, F., Valerio, M., Affronti, A., Orlando, E., Rosa Barcellona, M., Aburas, S., Dragoni, G., Campani, C., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Garuti, F., Gramenzi, A., Magalotti, D., Serra, C., Granito, A., Negrini, G., Napoli, L., Piscaglia, F., Morisco, Filomena, Guarino, Maria, Valvano, Maria R., Auriemma, Francesco, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Tovoli, Francesco, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Benvengù, Luisa, Gasbarrini, Antonio, Svegliati Baroni, Gianluca, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Marra, Fabio, Caporaso, Nicola, Trevisani, Franco, Sessa, Anna, Marafatto, Filippo, Peserico, Giulia, Pozzan, Caterina, Brunacci, Matteo, Moscatelli, Alessandro, Pellegatta, Gaia, Savarino, Vincenzo, Del Poggio, Paolo, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Lauria, Valentina, Pelecca, Giorgio, Mismas, Valeria, Rossi, Margherita, Attardo, Simona, Cavani, Giulia, Mega, Andrea, Rinninella, Emanuele, Ortolani, Alessio, Bevilacqua, Vittoria, Chiara Dall'Aglio, Anna, Ercolani, Giorgio, Fiorini, Erica, Casadei Gardini, Andrea, Lanzi, Arianna, Mirici Cappa, Federica, Missale, Gabriele, Porro, Emanuela, Marchetti, Fabiana, Valerio, Matteo, Affronti, Andrea, Orlando, Emanuele, Rosa Barcellona, Maria, Aburas, Sami, Dragoni, Gabriele, Campani, Claudia, Biselli, Maurizio, Bucci, Laura, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Garuti, Francesca, Gramenzi, Annagiulia, Magalotti, Donatella, Serra, Carla, Granito, Alessandro, Negrini, Giulia, Napoli, Lucia, Piscaglia, Fabio, Valvano, Maria R, Giannini, Edoardo G, and Foschi, Francesco G

Subjects
Oncology, Male, obesity, Databases, Factual, Hepatocellular carcinoma, 0302 clinical medicine, Risk Factors, Prospective cohort study, diabetes, Metabolic disorder, Liver Neoplasms, Diabetes, hepatocellular carcinoma, Middle Aged, Metabolic syndrome, Portal vein thrombosis, Italy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, medicine.medical_specialty, Carcinoma, Hepatocellular, Settore MED/12 - GASTROENTEROLOGIA, Obesity, metabolic syndrome, 03 medical and health sciences, Databases, Metabolic Diseases, Internal medicine, medicine, Diabetes Mellitus, Humans, Factual, Aged, Neoplasm Staging, Retrospective Studies, Hepatology, business.industry, Carcinoma, Hepatocellular, medicine.disease, Survival Analysis, BCLC Stage, Multivariate Analysis, diabete, Liver function, business
Abstract

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P=.021), larger tumours (P=.038), better liver function (higher percentage of Child-Pugh class A [P=.007] and MELD&nbsp

Published
2018

32. Abstracts of papers presented at the Sixth InternationalVerticillium Symposium Abstracts of papers presented at the Seventh Conference of the Entomological Society of Israel: June 19–23,1994 Hod Hotel, Dead Sea, Israel December 12, 1994 ARO, The Volcani Center, Bet Dagan, Israel

Author

Kening, L., Rouse, D. I., German, T. L., Roberts, D. M., Bainbridge, B. W., Evans, H. C., Heale, J. B., Koike, M., Watanabe, M., Nagao, H., Perez-Lara, Catalina, Pérez-Artés, Encarnación, Jiménez-Díaz, Rafael M., Barasubiye, Tharcisse, Richard, Claude, Dostaler, Daniel, Parent, Jean-Guy, Hamelin, Richard C., Laberge, Serge, Harris, D. C., Yang, J. R., Karapapa, V. K., Barbara, D. J., Carder, J. H., Morton, A., Tabrett, A. M., Rowe, Randall C., Botseas, Despina D., Wakatabe, D., Shiraishi, T., Iijima, T., Paplomatas, E. J., Elena, K., Portenko, Ljudmila G., Akimov, G. I., Poshnagova, Veronika G., Rataj-Guranowska, M., Walkowiak, I., (Bud) Platt, H. W., Robb, J., Nazar, R., Hu, X., Fitt, B. D. L., Melo, I. S., Brar, J. K., Huang, H. C., Kozub, G. C., Kokko, E. G., Coomber, S., Bejarano-Alcazar, J., Bianco-Lopez, M. A., Melero-Vara, J. M., Jiménez-Díaz, R. M., Lamers, J. G., Orenstein, Jana, Sabbah, S., Nachmias, A., Livescu, L., Tsror (Lahkim), Leah, Ben-Hador, G., Orion, D., Allen, S. J., Koike, S. T., Subbarao, K. V., Anne Hawke, Mary, Lazarovits, George, Mol, L., Ann Hawke, Mary, Termorshuizen, A. J., Dube, H. C., Ten, L. N., Faiziev, M. M., Romanova, L. A., Resende, Mario L. V., Cooper, Richard M., Flood, Julie, Beale, Michael H., Xu, H., Nazar, R. N., Pennypacker, B. W., Knievel, D. P., Risius, M. L., Leath, K. T., Gold, J., Ciccarese, F., Cirulli, M., Amenduni, M., Eldon, S., Hillocks, R. J., Chambers, D. A., Darby, P., Shadmanov, R. K., Hiemstra, J. A., Maharshak, G., Klein, L., Sadan, D., Gamliel, A., Grinstein, A., Peretz, I., Katan, J., Heiman, O., Varshavski, S., Melouk, H. A., Li, X., Damicone, J. P., Jackson, K. E., Fravel, D. R., Tjamos, E. C., Nagtzaam, M. P. M., Saito, E. S., Azevedo, J. L., Faull, J. L., Solarska, Ewa, Powelson, M. L., Cappaert, M. R., Christensen, N. W., Huisman, O. C., Davis, J. R., Sorensen, L. H., Schneider, A. T., Wysoki, M., Margalit, J., Zaritsky, A., Barak, Z., Markus, A., Boussiba, S., Cohen, S., Grinberg, M., Manasherob, R., Ben, E., Gazit, E., Oren, Z., Shai, Y., Peleg, N., Nissan, G., Navon, A., Keller, M., Strizhov, N., Regev, Avital, Sneh, B., Koncz, C., Schell, J., Zilberstein, Avian, Chejanovsky, N., Zilberberg, N., Zlotkin, E., Rivkin, H., Gurevitz, M., Faktor, O., Ben-Ze’ev, I. S., Gindin, Galina, Barash, I., Raccah, B., and Glazer, I.

Published
1995
Full Text
View/download PDF

33. Abstracts of papers presented at the 13th Conference of the Weed Science Society of Israel Abstracts of papers presented at the Third Israeli-Italian Phytopathological Symposium: January 24-25, 1994 The Hebrew University of Jerusalem, Faculty of Agriculture Rehovot, Israel June 14-17, 1994 Kefar haMaccabi, Israel

Author

Sachs, M., Boeken, B., Shachak, M., Shaham, G., Horowitz, M., Rosenberg, U., Yetah, N., Sheinboim, Y., Ohali, Y., Karmon, D., Nir, A., Raz, A., Barkai, J., Bucsbaum, H., Kleifeld, Y., Herzlinger, G., Blumenfeld, T., Golan, S., Chilf, T., Tsamir, G., Tal, A., Benyamini, Y., Rubin, B., Baum, D., Ovadia, A., Badawiah, J., Shachor, G., Zemer, B., Kedar, Y., Wasserman, M., Yona, A., Bar, Z., Graph, S., Luchinsky, U., Ohali, Y., Sibony, M., Varsano, Rina, Schonfeld, M., Lior, E., Kigel, J., Levy, Orit, Krugman, Tamar, Snape, J., Nevo, E., Gal, D., Ben-Yakir, D., Rosen, D., Yogev, M., Negbi, M., Levanon, D., Freund, Miriam, Yarden, O., Ben-Zvi-Assaraf, Orit, Mandelbaum, R. T., Wackett, L. P., Allan, Deborah L., Jacobsohn, R., Goldwasser, Y., Bargutti, A., Toledano, J., Levitin, E., Joel, D. M., Shamla, Miriam, Vriend, A., Flakchin, D., Palevitz, D., Russo, R., Berant, Y., Losner-Goshen, Dalia, Assayag, Michal, Garibaldi, A., Gullino, M. L., Migheli, Q., Aloi, C., Zimand, G., Elad, Y., Kritzman, G., Chet, I., Haran, S., Schickler, H., Oppenheim, A., Surico, G., Bogo, A., Sfalanga, A., Mugnai, L., Bonino, M., Piano, Serenella, Testoni, A., Droby, S., Wisniewski, M., Chalutz, E., Shoseyov, O., Pratella, G. C., Mari, M., Guizzardi, M., Bertolini, P., Freeman, S., Rodriguez, R. J., Cortesi, P., Smith, F. D., Minuto, A., Fallik, E., Grinberg, S., Gambourg, M., Klein, J., Lurie, S., Grinstein, A., Ramraz, Y., Riban, Y., Kirshner, G., Bazar, A., Halperin, I., Shlevin, E., Katan, J., Mahrer, Y., Ippolito, A., Lima, G., Nigro, F., Linsalata, V., Cascarano, N., Saks, Y., Barkai-Golan, R., Tamietti, G., Matta, A., Ben-Yephet, Y., Reuven, M., Lampel, M., Zveibel, A., Shtienberg, D., Cirulli, M., Ciccarese, F., Amenduni, M., Cohen, R., Nerson, H., Elkind, Y., Burger, Y., Offenbach, R., Afek, U., Aharoni, N., fnCarmeli, S., Roizer, L., Fang, D., Rodov, V., Ben-Yehoshua, S., Stefani, E., Bazzi, C., Ghedini, R., Mazzucchi, U., Austerweil, M., Zvieli, E., Ben-David, T., Gotlieb, Y., Steiner, B., Riban, Y., Gamliel, A., Katan, J., Klein, L., Ucko, O., Shtienberg, D., Lehrer, W., Retig, B., Kritzman, G., Austerweil, M., Warshavsky, S., Steiner, B., Dory, I., Caspi, H., Yarden, O., Paster, N., Barkai-Golan, R., Sparapano, L., Iacobellis, N. S., Scala, A., Tegli, S., Wattad, C., Kobiler, D., Dinoor, A., Prusky, D., Manulis, S., Valinsky, L., Kogan, N., Camele, I., Concetta Avigliano, A., Rana, G. L., Clark, E., Cirvilleri, G., Grantham, G., PRodriguez, R. J., Graniti, A., Mugnai, L., Surico, G., Esposito, A., Bruno, E., Corazza, L., Damiano, C., Ialongo, M. T., Frattarelli, A., Magnotta, A., Tsror, L., Causin, R., Montecchio, L., Mutto Accordi, S., Cacciola, S. O., Magnano di San Lio, G., Perrotta, G., Battilani, P., Racca, P., Rossi, V., Lichter, A., Gafni, Y., Barash, I., Bazzi, C., Vercesi, A., Sirtori, C., Literati, D., Setti, E., Ragazzi, A., Dellavalle, I., Mancini, F., Tanne, E., Shalamovitz, N., Spiegel, S., Rosner, A., Stein, A., Levy, S., Lilien-Kipnis, H., Rabiti, A. L., Betti, L., Torrigiani, P., Bagni, N., Brizzi, M., Marani, F., and Canova, A.

Published
1994
Full Text
View/download PDF

34. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

Author

Cazzagon N, Maddalo G, Giacomin A, Vanin V, Pozzan C, Del Poggio P, Rapaccini G, Di Nolfo AM, Benvegnù L, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Farinati F, The Italian Liver Cancer Group [. . ., DOMENICALI, MARCO, TREVISANI, FRANCO, ZOLI, MARCO, BOLONDI, LUIGI, BERNARDI, MAURO, Cazzagon, N, Trevisani, F, Maddalo, G, Giacomin, A, Vanin, V, Pozzan, C, Del Poggio, P, Rapaccini, G, Di Nolfo, AM, Benvegnù, L, Zoli, M, Borzio, F, Giannini, EG, Caturelli, E, Chiaramonte, M, Foschi, FG, Cabibbo, G, Felder, M, Ciccarese, F, Missale, G, Svegliati Baroni, G, Morisco, F, Pecorelli, A, Farinati, F., Di Nolfo, Am, Benvegn?, L, Giannini, Eg, Foschi, Fg, Morisco, Filomena, Farinati, F, CA Group, for the I. T. A. L. I., Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Del Poggio P, Rapaccini G, Di Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Pecorelli A, Farinati F, The Italian Liver Cancer (ITA.LI.CA) Group [.., Bernardi M, and ]

Subjects
Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Hepatitis C virus, hepatitis C, hepatocellular carcinoma, cirrhosis, medicine.disease_cause, Gastroenterology, Group B, Sex Factors, Internal medicine, Epidemiology, Prevalence, medicine, Humans, HEPATOCELLULAR CARCINOMA, CIRRHOSIS, Retrospective Studies, Hepatology, business.industry, Incidence, Liver Neoplasms, Age Factors, Retrospective cohort study, Hepatitis C, medicine.disease, Survival Analysis, digestive system diseases, Surgery, Italy, Hepatocellular carcinoma, Etiology, Female, business
Abstract

Background & Aims Hepatitis C virus (HCV) is the leading aetiological factor of HCC in the western world where, overall, its incidence is increasing, despite data suggesting an initial drop in some areas. The aim of this study was to evaluate epidemiology, clinical features and survival of HCV-related HCC (HCV-HCC) in a wide time range in Italy. Methods Multicentre retrospective study including 3695 patients prospectively recruited by the ITA.LI.CA group. Patients were classified into three subgroups according to aetiology (Group A[GA], pure HCV; Group B[GB], HCV + cofactors; and Group C[GC], non-HCV) and in 5 time cohorts (5 years each), according to the year of diagnosis. Age, gender, Child–Pugh score, modality of diagnosis, stage, presence of thrombosis/metastases, type of treatment and survival were analysed. Results A total of 1801 GA patients, 445 GB and 1333 GC were recruited. The number of GA patients peaked in the 1996–2000, gradually dropping thereafter (P

Published
2013
Full Text
View/download PDF

35. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria

Author

Ravaioli, M, Odaldi, F, Cucchetti, A, Trevisani, F, Piscaglia, F, De, P, V, Bertuzzo, V, Neri, F, Golfieri, R, Cappelli, A, D’Errico, A, Cescon, M, Del, G, M, Fallani, G, Siniscalchi, A, Morelli, M, Ciccarese, F, Di Marco, M, Farinati, F, Giannini, E, Pinna, A, De Pace, Bertuzzo, VR, Del Gaudio, Morelli, MC, Giannini, EG, Pinna, AD, Ravaioli, M, Odaldi, F, Cucchetti, A, Trevisani, F, Piscaglia, F, De, P, V, Bertuzzo, V, Neri, F, Golfieri, R, Cappelli, A, D’Errico, A, Cescon, M, Del, G, M, Fallani, G, Siniscalchi, A, Morelli, M, Ciccarese, F, Di Marco, M, Farinati, F, Giannini, E, Pinna, A, De Pace, Bertuzzo, VR, Del Gaudio, Morelli, MC, Giannini, EG, and Pinna, AD

Abstract

The objective of the study is to evaluate 10 years of down-staging strategy for liver transplantation (LT) with a median follow-up of 5 years. Data on long-term results are poor and less information is available for hepatocellular carcinoma (HCC) non-responder patients or those ineligible for down-staging. The outcome of 308 HCC candidates and the long-term results of 231 LTs for HCC performed between 2003 and 2013 were analyzed. HCCs were divided according to tumor stage and response to therapy: 145 patients were T2 (metering Milan Criteria, MC), 43 were T3 successfully down-staged to T2 (Down-Achieved), 20 were T3 not fully down-staged to T2 (Down-not Achieved), and 23 patients were T3 not receiving down-staging treatments (No-Down). The average treatment effect (ATE) of LT for T3 tumors was estimated using the outcome of 535 T3 patients undergoing non-LT therapies, using inverse probability weighting regression adjustment. The 24-month drop-out rate during waiting time was significantly higher in the down-staging groups: 27.6% vs. 9.2%, p < 0.005. After LT, the tumor recurrence rate was significantly different: MC 7.6%, Down-Achieved 20.9%, Down-not Achieved 31.6%, and No-Down 30.4% (p < 0.001). The survival rates at 5 years were: 63% in Down-Achieved, 62% in Down-not Achieved, 63% in No-Down, and 77% in MC (p = n.s.). The only variable related to a better outcome was the effective down-staging to T2 at the histological evaluation of the explanted liver: recurrence rate = 7.8% vs. 26% (p < 0.001) and 5-year patient survival = 76% vs. 67% (p < 0.05). The ATE estimation showed that the mean survival of T3-LT candidates was significantly better than that of T3 patients ineligible for LT [83.3 vs 39.2 months (+44.6 months); p < 0.001]. Long term outcome of T3 down-staged candidates was poorer than that of MC candidates, particularly for cases not achieving down-staging. However, their survival outcome was significantly better than that achieved with no

Published
2019

36. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

Author

BUCCI, LAURA, GARUTI, FRANCESCA, LENZI, BARBARA, PISCAGLIA, FABIO, ZOLI, MARCO, BERNARDI, MAURO, TREVISANI, FRANCO, BOLONDI, LUIGI, BISELLI, MAURIZIO, CARACENI, PAOLO, CUCCHETTI, ALESSANDRO, DOMENICALI, MARCO, GRAMENZI, ANNAGIULIA, Camelli, V, Farinati, F, Giannini, E, Ciccarese, F, Rapaccini, G, Di Marco, M, Caturelli, E, Borzio, F, Sacco, R, Maida, M, Felder, M, Morisco, F, Gasbarrini, A, Gemini, S, Foschi, F, Missale, G, Masotto, A, Affronti, A, Italian Liver Cancer Group, Bucci, L., Garuti, F., Camelli, V., Lenzi, B., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Trevisani, F, Olmi, S, on behalf of Italian Liver Cancer, (ITA. LI. CA) Group., Bucci, L, Garuti, F, Camelli, V, Lenzi, B, Farinati, F, Giannini, E, Ciccarese, F, Piscaglia, F, Rapaccini, G, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Maida, M, Felder, M, Morisco, F, Gasbarrini, A, Gemini, S, Foschi, F, Missale, G, Masotto, A, Affronti, A, Bernardi, M, Italian Liver Cancer (ITA.LI.CA.) Group, Bolondi, L, Biselli, M, Caraceni, P, Cucchetti, A, Domenicali, M, Gramenzi, A, Giannini, E. G, Rapaccini, G. L, Morisco, Filomena, Foschi, F. G, and Trevisani, F.

Subjects
Male, Sex Factor, Gastroenterology, Hepatitis, 0302 clinical medicine, alcoholic cirrhosi, Liver Function Tests, Retrospective Studie, Risk Factors, Esophageal and Gastric Varice, 80 and over, Age Factor, Pharmacology (medical), Age Factors, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Esophageal and Gastric Varices, Female, Hepatitis C, Hepatitis, Alcoholic, Humans, Liver Neoplasms, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Retrospective Studies, Sex Factors, Treatment Outcome, Venous Thrombosis, alpha-Fetoproteins, Medicine (all), medicine.diagnostic_test, Liver Function Test, Alcoholic, Liver Neoplasm, Hepatocellualr carinoma, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, epidemiology, 030211 gastroenterology & hepatology, Liver cancer, Viral hepatitis, Human, medicine.medical_specialty, Prognosi, 03 medical and health sciences, Internal medicine, medicine, Venous Thrombosi, Hepatology, business.industry, Risk Factor, Carcinoma, Cancer, Hepatocellular, medicine.disease, digestive system diseases, BCLC Stage, Proportional Hazards Model, Liver function, business, Liver function tests, HCV-related cirrhosi
Abstract

Summary Background Hepatitis C virus (HCV) and alcohol abuse are the main risk factors for hepatocellular carcinoma (HCC) in Western countries. Aim To investigate the role of alcoholic aetiology on clinical presentation, treatment and outcome of HCC as well as on each Barcelona Clinic Liver Cancer (BCLC) stage, as compared to HCV-related HCCs. Methods A total of 1642 HCV and 573 alcoholic patients from the Italian Liver Cancer (ITA.LI.CA) database, diagnosed with HCC between January 2000 and December 2012 were compared for age, gender, type of diagnosis, tumour burden, portal vein thrombosis (PVT), oesophageal varices, liver function tests, alpha-fetoprotein, BCLC, treatment and survival. Aetiology was tested as predictor of survival in multivariate Cox regression models and according to HCC stages. Results Cirrhosis was present in 96% of cases in both groups. Alcoholic patients were younger, more likely male, with HCC diagnosed outside surveillance, in intermediate/terminal BCLC stage and had worse liver function. After adjustment for the lead-time, median (95% CI) overall survival (OS) was 27.4 months (21.5–33.2) in alcoholic and 33.6 months (30.7–36.5) in HCV patients (P = 0.021). The prognostic role of aetiology disappeared when survival was assessed in each BCLC stage and in the Cox regression multivariate models. Conclusions Alcoholic aetiology affects survival of HCC patients through its negative effects on secondary prevention and cancer presentation but not through a greater cancer aggressiveness or worse treatment result. In fact, survival adjusted for confounding factors was similar in alcoholic and HCV patients.

Published
2015

37. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Author

Vitale, A, Lai, Q, Farinati, F, Bucci, L, Giannini, Eg, Napoli, L, Ciccarese, F, Rapaccini, Gl, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Cabibbo, G, Virdone, R, Marra, F, Felder, M, Morisco, F, Benvegnù, L, Gasbarrini, A, Svegliati-Baroni, G, Foschi, Fg, Missale, G, Masotto, A, Nardone, G, Colecchia, A, Bernardi, M, Trevisani, F, Pawlik, Tm, Italian Liver Cancer, (ITA. LI. CA) group., Vitale, Alessandro, Lai, Quirino, Farinati, Fabio, Bucci, Laura, Giannini, Edoardo G., Napoli, Lucia, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Pawlik, Timothy M., and D'Alessandro, Vitale

Subjects
Oncology, Male, Hepatocellular carcinoma, Tumor burden, Disease, Severity of Illness Index, Milan Criteria, Outcomes, Prognosis, 0302 clinical medicine, Risk Factors, Outcome, education.field_of_study, Liver Neoplasms, Gastroenterology, Middle Aged, Survival Rate, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, alpha-Fetoproteins, medicine.medical_specialty, Carcinoma, Hepatocellular, Prognosi, Settore MED/12 - GASTROENTEROLOGIA, Population, Milan criteria, End Stage Liver Disease, 03 medical and health sciences, Internal medicine, medicine, Humans, Neoplasm Invasiveness, Risk factor, education, Survival analysis, Aged, Proportional Hazards Models, Retrospective Studies, Hepatocellular carcinoma, Milan Criteria, Outcomes, Prognosis, Tumor burden, Surgery, Gastroenterology, business.industry, Proportional hazards model, medicine.disease, Blood Vessels, Surgery, business
Abstract

Background: Dichotomous models like Milan Criteria represent the routinely used tools for predicting the outcome of patients with hepatocellular carcinoma (HCC). However, a paradigm shift from a dichotomous to continuous prognostic stratification should represent a good strategy for improving the prediction process. Recently, the tumor burden score (TBS) has been proposed for selecting patients with colorectal liver metastases. To date, TBS has not been validated in a large HCC population. The main objective of this study was to evaluate the prognostic power of TBS in an HCC population treated with different curative and palliative modalities. Methods: Prospectively collected data from consecutive HCC patients managed in 24 institutions participating in the ITA.LI.CA group between Jan 2002 and Mar 2015 were analyzed (n = 4759). A sub-analysis focused on 3909 patients with the radiological evidence of vascular invasion or metastatic disease was also performed. Results: TBS demonstrated the best discriminative ability when compared to MC and other tumor-specific scores. At multivariable Cox regression analysis, TBS was an independent risk factor of overall survival, with a 6% increased risk for patient death for each point increase in TBS. At survival analysis, when TBS ≥ 8 was connected with MELD ≥ 15 and alpha-fetoprotein ≥ 1000 ng/mL, patients presenting all these three risk factors presented the worst results (p value < 0.0001). Conclusions: Survival prediction of HCC patients was very well done using TBS model, even stratifying the population in relation to the presence of metastases and/or vascular invasion. TBS model was the best in terms of discriminatory ability and goodness of fit when compared with other continuous or binary variables. Its incorporation in a model composed by tumor- and liver function-related variables further increases its survival prediction.

Published
2018

38. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

Author

Vitale, A, Farinati, F, Noaro, G, Burra, P, Pawlik, Tm, Bucci, L, Giannini, Eg, Faggiano, C, Ciccarese, F, Rapaccini, Gl, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Cabibbo, G, Virdone, R, Marra, F, Felder, M, Morisco, F, Benvegnù, L, Gasbarrini, A, Svegliati-Baroni, G, Foschi, Fg, Olivani, A, Masotto, A, Nardone, G, Colecchia, A, Fornari, F, Marignani, M, Vicari, S, Bortolini, E, Cozzolongo, R, Grasso, A, Aliberti, C, Bernardi, M, Frigo, Ac, Borzio, M, Trevisani, F, Cillo, U, CA) group, Italian Liver Cancer (ITA. LI., Vitale, Alessandro, Farinati, Fabio, Noaro, Giulia, Burra, Patrizia, Pawlik, Timothy M., Bucci, Laura, Giannini, Edoardo G., Faggiano, Chiara, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Fornari, Fabio, Marignani, Massimo, Vicari, Susanna, Bortolini, Emanuela, Cozzolongo, Raffaele, Grasso, Alessandro, Aliberti, Camillo, Bernardi, Mauro, Frigo, Anna Chiara, Borzio, Mauro, Trevisani, Franco, and Cillo, Umberto

Subjects
Male, Oncology, Databases, Factual, Liver cancer, non surgical therapy, prognostic system, surgical therapy, survival, hepatocellular carcinoma, stage, treatment, Kaplan-Meier Estimate, Cohort Studies, Liver disease, 0302 clinical medicine, Middle Aged, Sorafenib, Prognosis, Italy, 030220 oncology & carcinogenesis, Catheter Ablation, Disease Progression, Female, 030211 gastroenterology & hepatology, medicine.drug, Cohort study, medicine.medical_specialty, Carcinoma, Hepatocellular, Settore MED/12 - GASTROENTEROLOGIA, Clinical Decision-Making, Risk Assessment, Disease-Free Survival, Statistics, Nonparametric, 03 medical and health sciences, Internal medicine, medicine, Hepatectomy, Humans, Infusions, Intra-Arterial, Neoplasm Invasiveness, Survival analysis, Aged, Neoplasm Staging, Retrospective Studies, Analysis of Variance, Hepatology, business.industry, Reproducibility of Results, Cancer, Retrospective cohort study, medicine.disease, Survival Analysis, business, Progressive disease
Abstract

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score at restaging was compared with that of the Barcelona Clinic Liver Cancer, Hong Kong Liver Cancer, and Cancer of the Liver Italian Program systems. A multivariable Cox survival analysis was performed to identify baseline, restaging, or dynamic variables that were able to improve the predictive performance of the prognostic systems. At restaging, 35.3% of patients maintained stable disease; most patients were either down-staged by treatment (27.2%) or had disease progression (37.5%). The ITA.LI.CA scoring system at restaging demonstrated the best prognostic performance in both the training and validation cohorts (c-index 0.707 and 0.722, respectively) among all systems examined. On multivariable analysis, several variables improved the prognostic ability of the ITA.LI.CA score at restaging, including progressive disease after the first treatment, Model for End-Stage Liver Disease at restaging, and choice of nonsurgical treatment as additional therapy. A new ITA.LI.CA restaging model was created that demonstrated high discriminative power in both the training and validation cohorts (c-index 0.753 and 0.745, respectively). Conclusion: Although the ITA.LI.CA score demonstrated the best prognostic performance at restaging, other variables should be considered to improve the prognostic assessment of patients at the time of deciding additional therapies for HCC.

Published
2018

40. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

Author

Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi M, Biselli M, Caraceni P, Domenicali M, Garuti F, Gramenzi A, Lenzi B, Magalotti D, Cescon M, Ravaioli M, Del Poggio P, Olmi S, Rapaccini GL, Balsamo C, Di Nolfo MA, Vavassori E, Alberti A, Benvegnù L, Gatta A, Giacomin A, Vanin V, Pozzan C, Maddalo G, Giampalma E, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Roselli P, Dell'Isola S, Ialungo AM, Risso D, Marenco S, Sammito G, Bruzzone L, Bosco G, Grieco A, Pompili M, Rinninella E, Siciliano M, Chiaramonte M, Guarino M, Cammà C, Maida M, Costantino A, Barcellona MR, Schiadà L, Gemini S, Lanzi A, Stefanini GF, Dall'Aglio AC, Cappa FM, Suzzi A, Mussetto A, Treossi O, Missale G, Porro E, Mismas V, Vivaldi C, Bolondi L, Zoli M, Granito A, Malagotti D, Tovoli F, Trevisani F, Venerandi L, Brandi G, Cucchetti A, Bugianesi E, Vanni E, Mezzabotta L, Cabibbo G, Petta S, Fracanzani A, Fargion S, Marra F, Fani B, Biasini E, Sacco R, CAPORASO, NICOLA, Colombo M, D'Ambrosio R, Crocè LS, Patti R, Giannini EG, Loria P, Lonardo A, Baldelli E, Miele L, Farinati F, Borzio M, Dionigi E, Soardo G, Caturelli E, Ciccarese F, Virdone R, Affronti A, Foschi FG, Borzio F., MORISCO, FILOMENA, Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi, M, Biselli, M, Caraceni, P, Domenicali, M, Garuti, F, Gramenzi, A, Lenzi, B, Magalotti, D, Cescon, M, Ravaioli, M, Del Poggio, P, Olmi, S, Rapaccini, Gl, Balsamo, C, Di Nolfo, Ma, Vavassori, E, Alberti, A, Benvegnù, L, Gatta, A, Giacomin, A, Vanin, V, Pozzan, C, Maddalo, G, Giampalma, E, Cappelli, A, Golfieri, R, Mosconi, C, Renzulli, M, Roselli, P, Dell'Isola, S, Ialungo, Am, Risso, D, Marenco, S, Sammito, G, Bruzzone, L, Bosco, G, Grieco, A, Pompili, M, Rinninella, E, Siciliano, M, Chiaramonte, M, Guarino, M, Cammà, C, Maida, M, Costantino, A, Barcellona, Mr, Schiadà, L, Gemini, S, Lanzi, A, Stefanini, Gf, Dall'Aglio, Ac, Cappa, Fm, Suzzi, A, Mussetto, A, Treossi, O, Missale, G, Porro, E, Mismas, V, Vivaldi, C, Bolondi, L, Zoli, M, Granito, A, Malagotti, D, Tovoli, F, Trevisani, F, Venerandi, L, Brandi, G, Cucchetti, A, Bugianesi, E, Vanni, E, Mezzabotta, L, Cabibbo, G, Petta, S, Fracanzani, A, Fargion, S, Marra, F, Fani, B, Biasini, E, Sacco, R, Morisco, Filomena, Caporaso, Nicola, Colombo, M, D'Ambrosio, R, Crocè, L, Patti, R, Giannini, Eg, Loria, P, Lonardo, A, Baldelli, E, Miele, L, Farinati, F, Borzio, M, Dionigi, E, Soardo, G, Caturelli, E, Ciccarese, F, Virdone, R, Affronti, A, Foschi, Fg, Borzio, F., Fabio Piscagliaxxx, Gianluca Svegliati-Baroni, Andrea Barchetti, Anna Pecorellixxx, Sara Marinellixxx, Claudio Tiribelli, and, Stefano Bellentani, on behalf of the HCC-NAFLD Italian Study Group [, Mauro Bernardi, Maurizio Biselli, Paolo Caraceni, Marco Domenicali, Francesca Garuti, Annagiulia Gramenzi, Barbara Lenzi, Donatella Magalotti, Matteo Cescon, Matteo Ravaioli, Emanuela Giampalma, Rita Golfieri, Cristina Mosconi, Luigi Bolondi, Marco Zoli, Alessandro Granito, Francesco Tovoli, Franco Trevisani, Laura Venerandi, Giovanni Brandi, Alessandro Cucchetti, ], DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Da definire, Croce', Saveria, and HCC NAFLD Italian Study, Group

Subjects
Male, Cirrhosis, Survival, Chronic liver disease, Gastroenterology, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Nonalcoholic fatty liver disease, 80 and over, Prospective Studies, Chronic, Prospective cohort study, Aged, 80 and over, Medicine (all), Liver Neoplasms, hepatocellular carcinoma, Middle Aged, Hepatitis C, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Competing risk analysi, 030211 gastroenterology & hepatology, Female, Non Alcoholic SteatoHepatitis=NASH, Human, medicine.medical_specialty, Aged, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Humans, Hepatology, Competing risk analysis, Milan criteria, 03 medical and health sciences, Internal medicine, medicine, Survival rate, business.industry, Settore MED/09 - MEDICINA INTERNA, Carcinoma, nutritional and metabolic diseases, Hepatocellular, medicine.disease, digestive system diseases, Nonalcoholic fatty liver disease, hepatocellular carcinoma, clinical patterns, business, clinical patterns
Abstract

none 31 no Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Regardless of tumor stage, survival was significantly shorter (P = 0.017) in patients with NAFLD-HCC, 25.5 months (95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P = nonsignificant) CONCLUSIONS: NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment. Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;] Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;]

Published
2016

41. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist

Author

Sverzellati, N, Odone, A, Silva, M, Polverosi, R, Florio, C, Cardinale, L, Cortese, G, Addonisio, G, Zompatori, M, Dalpiaz, G, Piciucchi, S, Larici, A, Agostini, C, Albera, C, Attinà, D, Battista, G, Bertelli, E, Bertorelli, G, Bnà, C, Bonifazi, M, Bonomo, L, Borghesi, A, Calandriello, L, Caminati, A, Capannelli, D, Cerri, S, Ciccarese, F, Colombi, D, Confalonieri, M, Del Ciello, A, della Casa, G, Dore, R, Falaschi, F, Farchione, A, Feragalli, B, Franchi, P, Gavelli, G, Harari, S, Luppi, F, Maggi, F, Mazzei, M, Mereu, M, Milanese, G, Palmucci, S, Patea, R, Pesci, A, Piolanti, M, Poletti, V, Rea, G, Richeldi, L, Rogliani, P, Romei, C, Rottoli, P, Sanduzzi-Zamparelli, A, Sebastiani, A, Sergiacomi, G, Soardi, G, Spaggiari, L, Spagnolo, P, Tomassetti, S, Trisolini, R, Valentini, A, Vancheri, C, Vespro, V, Volterrani, L, Sverzellati, Nicola, Odone, Anna, Silva, Mario, Polverosi, Roberta, Florio, Carlo, Cardinale, Luciano, Cortese, Giancarlo, Addonisio, Giancarlo, Zompatori, Maurizio, Dalpiaz, Giorgia, Piciucchi, Sara, Larici, Anna Rita, Agostini, Carlo, Albera, Carlo, Attinà, Domenico, Battista, Giuseppe, Bertelli, Elena, Bertorelli, Giuseppina, Bnà, Claudio, Bonifazi, Martina, Bonomo, Lorenzo, Borghesi, Andrea, Calandriello, Lucio, Caminati, Antonella, Capannelli, Diana, Cerri, Stefania, Ciccarese, Federica, Colombi, Davide, Confalonieri, Marco, Del Ciello, Annaemilia, della Casa, Giovanni, Dore, Roberto, Falaschi, Fabio, Farchione, Alessandra, Feragalli, Beatrice, Franchi, Paola, Gavelli, Giampaolo, Harari, Sergio, Luppi, Fabrizio, Maggi, Fabio, Mazzei, Maria Antonietta, Mereu, Manuela, Milanese, Gianluca, Palmucci, Stefano, Patea, Rosa Lucia, Pesci, Alberto, Piolanti, Marco, Poletti, Venerino, Rea, Gaetano, Richeldi, Luca, Rogliani, Paola, Romei, Chiara, Rottoli, Paola, Sanduzzi-Zamparelli, Alessandro, Sebastiani, Alfredo, Sergiacomi, Gianluigi, Soardi, Gian Alberto, Spaggiari, Lucia, Spagnolo, Paolo, Tomassetti, Sara, Trisolini, Rocco, Valentini, Adele, Vancheri, Carlo, Vespro, Valentina, Volterrani, Luca, Sverzellati, N, Odone, A, Silva, M, Polverosi, R, Florio, C, Cardinale, L, Cortese, G, Addonisio, G, Zompatori, M, Dalpiaz, G, Piciucchi, S, Larici, A, Agostini, C, Albera, C, Attinà, D, Battista, G, Bertelli, E, Bertorelli, G, Bnà, C, Bonifazi, M, Bonomo, L, Borghesi, A, Calandriello, L, Caminati, A, Capannelli, D, Cerri, S, Ciccarese, F, Colombi, D, Confalonieri, M, Del Ciello, A, della Casa, G, Dore, R, Falaschi, F, Farchione, A, Feragalli, B, Franchi, P, Gavelli, G, Harari, S, Luppi, F, Maggi, F, Mazzei, M, Mereu, M, Milanese, G, Palmucci, S, Patea, R, Pesci, A, Piolanti, M, Poletti, V, Rea, G, Richeldi, L, Rogliani, P, Romei, C, Rottoli, P, Sanduzzi-Zamparelli, A, Sebastiani, A, Sergiacomi, G, Soardi, G, Spaggiari, L, Spagnolo, P, Tomassetti, S, Trisolini, R, Valentini, A, Vancheri, C, Vespro, V, Volterrani, L, Sverzellati, Nicola, Odone, Anna, Silva, Mario, Polverosi, Roberta, Florio, Carlo, Cardinale, Luciano, Cortese, Giancarlo, Addonisio, Giancarlo, Zompatori, Maurizio, Dalpiaz, Giorgia, Piciucchi, Sara, Larici, Anna Rita, Agostini, Carlo, Albera, Carlo, Attinà, Domenico, Battista, Giuseppe, Bertelli, Elena, Bertorelli, Giuseppina, Bnà, Claudio, Bonifazi, Martina, Bonomo, Lorenzo, Borghesi, Andrea, Calandriello, Lucio, Caminati, Antonella, Capannelli, Diana, Cerri, Stefania, Ciccarese, Federica, Colombi, Davide, Confalonieri, Marco, Del Ciello, Annaemilia, della Casa, Giovanni, Dore, Roberto, Falaschi, Fabio, Farchione, Alessandra, Feragalli, Beatrice, Franchi, Paola, Gavelli, Giampaolo, Harari, Sergio, Luppi, Fabrizio, Maggi, Fabio, Mazzei, Maria Antonietta, Mereu, Manuela, Milanese, Gianluca, Palmucci, Stefano, Patea, Rosa Lucia, Pesci, Alberto, Piolanti, Marco, Poletti, Venerino, Rea, Gaetano, Richeldi, Luca, Rogliani, Paola, Romei, Chiara, Rottoli, Paola, Sanduzzi-Zamparelli, Alessandro, Sebastiani, Alfredo, Sergiacomi, Gianluigi, Soardi, Gian Alberto, Spaggiari, Lucia, Spagnolo, Paolo, Tomassetti, Sara, Trisolini, Rocco, Valentini, Adele, Vancheri, Carlo, Vespro, Valentina, and Volterrani, Luca

Abstract

Objectives: To apply the Delphi exercise with iterative involvement of radiologists and pulmonologists with the aim of defining a structured reporting template for high-resolution computed tomography (HRCT) of patients with fibrosing lung disease (FLD). Methods: The writing committee selected the HRCT criteria—the Delphi items—for rating from both radiology panelists (RP) and pulmonology panelists (PP). The Delphi items were first rated by RPs as “essential”, “optional”, or “not relevant”. The items rated “essential” by < 80% of the RP were selected for the PP rating. The format of reporting was rated by both RP and PP. Results: A total of 42 RPs and 12 PPs participated to the survey. In both Delphi round 1 and 2, 10/27 (37.7%) items were rated “essential” by more than 80% of RP. The remaining 17/27 (63.3%) items were rated by the PP in round 3, with 2/17 items (11.7%) rated “essential” by the PP. PP proposed additional items for conclusion domain, which were rated by RPs in the fourth round. Poor consensus was observed for the format of reporting. Conclusions: This study provides a template for structured report of FLD that features essential items as agreed by expert thoracic radiologists and pulmonologists

Published
2018

42. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study

Author

Vitale A, Burra P, Frigo AC, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U, Italian Liver Cancer group, TREVISANI, FRANCO, PISCAGLIA, FABIO, ZOLI, MARCO, BERNARDI, MAURO, BOLONDI, LUIGI, BISELLI, MAURIZIO, CARACENI, PAOLO, CUCCHETTI, ALESSANDRO, DOMENICALI, MARCO, GRAMENZI, ANNAGIULIA, Vitale, A., Burra, P., Frigo, A. C., Trevisani, F., Farinati, F., Spolverato, G., Volk, M., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Cabibbo, G., Felder, M., Gasbarrini, A., Sacco, R., Foschi, F. G., Missale, G., Morisco, F., Svegliati Baroni, G., Virdone, R., Cillo, U, Olmi, S, on behalf of Italian Liver Cancer, (ITA. LI. CA) group., Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, Cillo, Umberto, Guarino, Maria, Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U, Italian Liver Cancer (ITA.LI.CA) group, Bernardi M, Bolondi L, Biselli M, Caraceni P, Cucchetti A, Domenicali M, and Gramenzi A

Subjects
Male, medicine.medical_specialty, Cirrhosis, Carcinoma, Hepatocellular, Loco-regional therapie, Hepatocellular carcinoma, Settore MED/12 - GASTROENTEROLOGIA, Hepatitis C virus, Kaplan-Meier Estimate, medicine.disease_cause, Gastroenterology, Cohort Studies, Liver disease, Interquartile range, Internal medicine, medicine, Humans, Best supportive care, Liver resection, Loco-regional therapies, Survival benefit, Aged, Female, Italy, Liver Neoplasms, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prognosis, Treatment Outcome, Medicine (all), Hepatology, BEST SUPPORTING CARE, Cirrhosi, Performance status, business.industry, CIRRHOISIS, Carcinoma, Hepatocellular, medicine.disease, BCLC Stage, Liver cancer, business
Abstract

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Results After stratifying for BCLC stage, the median net survival benefit of resection over LRT was: BCLC 0 = 62% (40%, 82%), A = 45% (13%, 65%), B = 46% (9%, 76%), C = -16% (-55%, 33%). Model for end-stage liver disease (MELD) score >9, Child B class, and performance status (PST) = 2 were the main risk factors for liver resection. 1181 Child A patients (57%) with MELD ≤9 and PST 9 or PST = 2 or Child B class), resection did not prove any survival benefit over LRT. Conclusions Resection could result in survival benefit over LRT for HCC patients regardless of their BCLC stage, provided that liver dysfunction (Child B or MELD >9) and PST >1 are absent.

Published
2014

43. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

Author

Cucchetti A., Trevisani F., Pecorelli A., Erroi V., Farinati F., Ciccarese F., Rapaccini G. L., Di Marco M., Caturelli E., Giannini E. G., Zoli M., Borzio F., Cabibbo G., Felder M., Gasbarrini A., Sacco R., Foschi F. G., Missale G., Morisco F., Baroni G. S., Virdone R., Bernardi M., Pinna A. D., Bolondi L., Biselli M., Caraceni P., Garuti F., Gramenzi A., Lenzi B., Magalotti D., Piscaglia F., Serra C., Ravaioli M., Venerandi L., Del Poggio P., Olmi S., Balsamo C., Di Nolfo M. A., Vavassori E., Alberti A., Benvegnu L., Gatta A., Giacomin A., Vanin V., Pozzan C., Maddalo G., Giampalma E., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Dell'Isola S., Ialungo A. M., Roselli P., Risso D., Marenco S., Sammito G., Bruzzone L., Bosco G., Grieco A., Pompili M., Rinninella E., Siciliano M., Chiaramonte M., Guarino M., Camma C., Maida M., Di Martino A., Barcellona M. R., Schiada L., Gemini S., Biasini E., Porro E., del Ricambio M., Mismas V., Vivaldi C., Cucchetti, A, Trevisani, F, Pecorelli, A, Erroi, V, Farinati, F, Ciccarese, F, Rapaccini, Gl, Di Marco, M, Caturelli, E, Giannini, Eg, Zoli, M, Borzio, F, Cabibbo, G, Felder, M, Gasbarrini, A, Sacco, R, Foschi, Fg, Missale, G, Morisco, Filomena, Baroni, G, Virdone, R, Bernardi, M, Pinna, Ad, Italian Liver Cancer, Group, Alessandro, Cucchetti, Franco, Trevisani, Anna, Pecorelli, Virginia, Erroi, Fabio, Farinati, Francesca, Ciccarese, Gian, Lodovico Rapaccini, Mariella Di, Marco, Eugenio, Caturelli, Edoardo, G. Giannini, Marco, Zoli, Franco, Borzio, Giuseppe, Cabibbo, Martina, Felder, Antonio, Gasbarrini, Rodolfo, Sacco, Francesco, Giuseppe Foschi, Gabriele, Missale, Filomena, Morisco, Gianluca, Svegliati Baroni, Roberto, Virdone, Mauro, Bernardi, Antonio D., Pinna, for the Italian Liver Cancer Group [.., Bolondi, Luigi, Maurizio, Biselli, Piscaglia, Fabio, ]., Cucchetti, A., Trevisani, F., Pecorelli, A., Erroi, V., Farinati, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Giannini, E. G., Zoli, M., Borzio, F., Cabibbo, G., Felder, M., Gasbarrini, A., Sacco, R., Foschi, F. G., Missale, G., Morisco, F., Baroni, G. S., Virdone, R., Bernardi, M., Pinna, A. D., Bolondi, L., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Lenzi, B., Magalotti, D., Piscaglia, F., Serra, C., Ravaioli, M., Venerandi, L., Del Poggio, P., Olmi, S., Balsamo, C., Di Nolfo, M. A., Vavassori, E., Alberti, A., Benvegnu, L., Gatta, A., Giacomin, A., Vanin, V., Pozzan, C., Maddalo, G., Giampalma, E., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Dell'Isola, S., Ialungo, A. M., Roselli, P., Risso, D., Marenco, S., Sammito, G., Bruzzone, L., Bosco, G., Grieco, A., Pompili, M., Rinninella, E., Siciliano, M., Chiaramonte, M., Guarino, M., Camma, C., Maida, M., Di Martino, A., Barcellona, M. R., Schiada, L., Gemini, S., Biasini, E., Porro, E., del Ricambio, M., Mismas, V., and Vivaldi, C.

Subjects
Male, medicine.medical_specialty, Pediatrics, Carcinoma, Hepatocellular, Time Factors, Hepatocellular carcinoma, Settore MED/12 - GASTROENTEROLOGIA, Disease, Gastroenterology, Bias, Internal medicine, Overall survival, medicine, Humans, Early Detection of Cancer, Aged, Estimation, Surveillance, Hepatology, business.industry, Liver Neoplasms, medicine.disease, digestive system diseases, Lead time bias, Cirrhosis, Female, business, Lead-time bias, Follow-Up Studies
Abstract

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Methods: One-thousand three-hundred and eighty Child–Pugh class A/B patients from the ITA.LI.CA database, in whom HCC was detected during semiannual surveillance (n = 850), annual surveillance (n = 234) or when patients came when symptomatic (n = 296), were selected. Lead-time was estimated by means of appropriate formulas and Monte Carlo simulation, including 1000 patients for each arm. Results: The 5-year overall survival after HCC diagnosis was 32.7% in semiannually surveilled patients, 25.2% in annually surveilled patients, and 12.2% in symptomatic patients (p

Published
2014

44. A sustainable management of corky root and root-knot nematodes by the biocontrol agent APHANOCLADIUM ALBUM ISOLATE MX-95

Author

Sasanelli N., Toderas I., Ciccarese F., Iurcu-Straistaru E., Rusu S., Toderas L., Renco M., Franchi M., Gallo M., Bivol A., and Gologan I.

Subjects
bio-nematicide, plant protection, Pyrenochaeta lycopersici, Meloidogyne incognita, chitinolytic fungus
Abstract

A trial was carried out in a plastic house on tomato to assess the efficacy of the chitinolytic fungus Aphanocladium album isolate MX-95 (AA MX-95) against the soil borne pathogen Pyrenochaeta lycopersici and the root-knot nematode Meloidogyne incognita. Treatments were: a) AA MX-95 applied in sub irrigation at 2,5 L./plot (1,2 x 107 CFU/mL., conidial suspension) in pre transplant (20 days), transplant and in post transplant (2 times every 20 days) + root dipping (5 min - conc.1,2 x 107 CFU/mL) at transplant); b) as before indicated without treatment in pre transplant; c) root dipping and d) dazomet (chemical control) applied 30 days before transplant at 600 Kg./ha.Untreated plots served as control. As significant yield increase and a reduction of severity of corky root and nematode attacks were observed in AA MX-95 and dazomet treated plots in comparison to control. High positive correlations were found between the symptoms caused on tomato root by M. incognita and P. lycopersici.

Published
2017

45. Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival

Author

Carr, Bi, Guerra, V, Giannini, Eg, Farinati, Fabio, Ciccarese, F, Rapaccini, Gl, Di Marco, M, Benvegnu', Luisa, Zoli, M, Borzio, F, Caturelli, E, Chiaramonte, M, Trevisani, F, Italian Liver Cancer Group, Carr, Brian I, Guerra, Vito, Giannini, Edoardo G., Farinati, Fabio, Ciccarese, Francesca, Rapaccini, Gian Ludovico, Di Marco, Maria, Benvegnù, Luisa, Zoli, Marco, Borzio, Franco, Caturelli, Eugenio, Chiaramonte, Maria, and Trevisani, Franco

Subjects
Blood Platelets, Male, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, Clinical Biochemistry, Gastroenterology, Pathology and Forensic Medicine, Liver Function Tests, Retrospective Studie, Internal medicine, medicine, Humans, Platelet, Prospective Studies, alpha-Fetoprotein, neoplasms, Retrospective Studies, Aged, Neoplasm Staging, Tumor size, Liver Function Test, business.industry, Data Collection, Liver Neoplasms, Middle Aged, medicine.disease, digestive system diseases, Portal vein thrombosis, Prospective Studie, Italy, Oncology, Liver Neoplasm, Hepatocellular carcinoma, Blood platelet counts, Blood Platelet, Female, alpha-Fetoproteins, Liver function, Risk of death, Bilirubin levels, business, Human
Abstract

Background Hepatocellular carcinoma (HCC) is a heterogeneous disease with both tumor and liver factors being involved. Aims To investigate HCC clinical phenotypes and factors related to HCC size. Methods Prospectively-collected HCC patients' data from a large Italian database were arranged according to the maximum tumor diameter (MTD) and divided into tumor size terciles, which were then compared in terms of several common clinical parameters and patients' survival. Results An higer MTD tercile was significantly associated with increased blood alpha-fetoprotein (AFP), gamma-glutamyl transpeptidase (GGTP), and platelet levels. Patients with higher platelet levels had larger tumors and higher GGTP levels, with lower bilirubin levels. However, patients with the highest AFP levels had larger tumors and higher bilirubin levels, reflecting an aggressive biology. AFP correlation analysis revealed the existence of 2 different groups of patients: those with higher and with lower AFP levels, each with different patient and tumor characteristics. The Cox proportional-hazard model showed that a higher risk of death was correlated with GGTP and bilirubin levels, tumor size and number, and portal vein thrombosis (PVT), but not with AFP or platelet levels. Conclusions An increased tumor size was associated with increased blood platelet counts, AFP and GGTP levels. Platelet and AFP levels were important indicators of tumor size, but not of survival.

Published
2014
Full Text
View/download PDF

46. Prognosis of untreated hepatocellular carcinoma

Author

Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Borzio F, Chiaramonte M, Italian Liver Cancer group […, Garuti F, Lenzi B, Magalotti D, Serra C, BOLONDI, LUIGI, ZOLI, MARCO, TREVISANI, FRANCO, BERNARDI, MAURO, BISELLI, MAURIZIO, CARACENI, PAOLO, CUCCHETTI, ALESSANDRO, DOMENICALI, MARCO, GRAMENZI, ANNAGIULIA, PISCAGLIA, FABIO, Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F, Italian Liver Cancer (ITA.LI.CA) group […, Bernardi M, Biselli M, Caraceni P, Cucchetti A, Domenicali M, Garuti F, Gramenzi A, Lenzi B, Magalotti D, Piscaglia F, Serra C, and …]

Subjects
Male, medicine.medical_specialty, Cirrhosis, PROGNOSIS, Carcinoma, Hepatocellular, Settore MED/12 - GASTROENTEROLOGIA, Gastroenterology, Cohort Studies, Internal medicine, Carcinoma, medicine, Humans, Decompensation, HEPATOCELLULAR CARCINOMA, Cause of death, Aged, Neoplasm Staging, Aged, 80 and over, Hepatology, business.industry, CIRRHOISIS, Liver Neoplasms, Middle Aged, medicine.disease, BCLC Stage, Surgery, Italy, Hepatocellular carcinoma, Multivariate Analysis, SURVIVAL, Female, Liver cancer, business
Abstract

The prognosis of untreated patients with hepatocellular carcinoma (HCC) is heterogeneous, and survival data were mainly obtained from control arms of randomized studies. Clinical practice data on this topic are urgently needed, so as to help plan studies and counsel patients. We assessed the prognosis of 600 untreated patients with HCC managed by the Italian Liver Cancer Group. Prognosis was evaluated by subdividing patients according to the Barcelona Clinic Liver Cancer (BCLC) classification. We also assessed the main demographic, clinical, and oncological determinants of survival in the subgroup of patients with advanced HCC (BCLC C). Advanced (BCLC C: n = 138; 23.0%) and end-stage HCC (BCLC D; n = 210; 35.0%) represented the majority of patients. Overall median survival was 9 months, and the principal cause of death was tumor progression (n = 279; 46.5%). Patients' median survival progressively and significantly decreased as BCLC stage worsened (BCLC 0: 38 months; BCLC A: 25 months; BCLC B: 10 months; BCLC C: 7 months; BCLC D: 6 months; P 3) HCC (HR = 1.79; 95% CI = 1.21-2.63; P = 0.003) were independent predictors of survival in patients with advanced HCC (BCLC C). CONCLUSION: BCLC adequately predicts the prognosis of untreated HCC patients. In untreated patients with advanced HCC, female gender, clinical decompensation of cirrhosis, and multinodular tumor are independent prognostic predictors and should be taken into account for patient stratification in future therapeutic studies.

Published
2015

48. SELECTED ABSTRACTS OF PAPERS PRESENTED AT THE 3rd INTERNATIONAL VERTICILLIUM SYMPOSIUM

Author

BEN-YEPHET, Y., SITI, E., FRANK, Z., BISHOP, C.D., COOPER, R.M., BOISOT, T., DUBOUCHET, J., PERESSE, M., BOISSON, C., LAHLOU, H., BUSCH, L.V., SMITH, E.A., ROBB, J., CHRISTIAS, C., TJAMOS, E., ZIOUDROU, C., KORNAROS, E., CIRULLI, M., CICCARESE, F., COOSEMANS, J., DAVIS, J.R., PAVEK, J.J., CORSINI, D.L., DUBE, H.C., MATHUR, S., BORDIA, S., EBBELS, D.L., FRANCIS, A., EVANS, G., KALDOR, J., GONDRAN, J., GUPTA, D.P., HEALE, J.B., CLARKSON, J.M., HARRIS, G.P., KRIKUN, J., ORION, D., NACHMIAS, A., MACE, M.E., BELL, A.A., McGEARY, F.M., HASTIE, A.C., MELOUK, H.A., WADSWORTH, D.F., MILTON, J.M., ONUORAH, O.M.O., MOREAU, M., CATESSON, A.M., MUROMTSEV, G.S., LAGUTINA, T.M., GLOBUS, G.A., STRUNNIKOVA, O.K., CHERNIAVEVA, I.I., MUSSEL, H., STILWELL, P.C., PINKAS, Y., KARIV, A., PUHALLA, J.E., HUMMEL, M., BUSCH, L., SMITH, A., SEDUN, F.S., SACKSTON, W.E., STREET, P.F.S., THANASSOULOPOULOS, C.C., BIRIS, D.A., TJAMOS, E.C., CHITZANIDIS, A., TYPAS, M.A., WHITNEY, N.J., HUNG, K.S., WILHELM, S., and ZINKERNAGEL, V.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results